Skip to main content

Table 1 Admission demographic data of study population

From: A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan

  Non-pregnant women Pregnant women P-value
  Median (Range) Median (Range)  
Number of patients 12 12 -
Daily piperaquine (phosphate) dose (mg/kg) 18.1 (15.1-24.2) 17.6 (13.6-21.7) 0.884
Daily piperaquine (base) dose (mg/kg) 10.5 (8.71-13.9) 10.2 (7.83-12.5) 0.884
Age (years) 21.0 (16.0-43.0) 26.0 (18.0-33.0) 0.977
Body weight (kg) 53.0 (44.0-81.0) 59.0 (50.0-72.0) 0.544
Height (cm) 163 (150–174) 166 (150–174) 0.908
Estimated gestational age (weeks) - 32.0 (15.3–40.1) -
Parasitemia (parasites/μL) 13200 (936–68700) 12900 (624–118000) 0.488
Days of fever 2.5 (1–6) 3 (1–6) 0.095
Fever (°C) 38.3 (36.7-40.0) 38.2 (36.6-39.9) 0.795
Haemoglobin (g/dL) 8.70 (7.60-11.5) 9.65 (8.00-12.0) 0.099
Urea (mg/dL) 26.0 (24.0-28.0) 25.0 (24.0-28.0) 0.036
Serum glutamic pyruvic transaminase (IU/L) 5.00 (2.00-10.0) 4.50 (2.00-9.00) 0.445
Serum glutamic oxaloacetic transaminase (IU/L) 13.5 (2.00-18.0) 13.0 (3.00-21.0) 0.727
  1. The p-values are calculated using the Mann–Whitney U-test.